ELITE PHARMACEUTICALS INC /NV/ (ELTP) stock intrinsic value fair value estimate & owner earnings analysis

Elite Pharmaceuticals is a U.S. generic drug manufacturer that makes tablets and capsules, including several federally controlled central-nervous-system stimulants (generic versions of Adderall and Adderall XR), an opioid/analgesic combination, and other generics, sold both under its own "Elite Labs" label and under contract manufacturing and licensing arrangements with other companies. The business went through a real transformation in the last three fiscal years. After becoming profitable for the first time a few years ago, revenue has grown rapidly, driven mainly by new product launches moving to the higher-margin, self-branded Elite Labs line — most notably a generic version of Vyvanse (lisdexamfetamine), plus newer launches of an oxycodone/acetaminophen combination, naltrexone, and phentermine tablets. However, the most recently reported quarter shows this growth has already begun to cool: revenue came in about 20% below the same quarter a year earlier. Revenue is also concentrated — two customers accounted for roughly three-quarters of last year's sales — so a change in either relationship can move results materially. Because of this, we did not simply extend the recent growth rate forward. Instead we anchored the valuation on the median of the last five fiscal years' owner earnings per share, which lands well below the most recent peak year, and built the growth path from there assuming a sharp slowdown from the recent pace. Our bear case assumes the recent slowdown continues, competitive or customer pressure further compresses the newly launched products' economics, and owner earnings settle at a permanently lower, roughly flat level going forward. Our base case assumes growth decelerates quickly from the recent triple-digit pace to the high single digits within a few years, then to a very low, roughly flat rate over the long run, consistent with a business that keeps some of its edge from a steady cadence of new drug approvals but faces normal generic-drug price erosion on older products. Our bull case assumes the recent product launches keep contributing, additional approvals continue at a healthy pace, and margins keep benefiting from the shift to the company's own label, without a customer-related setback. We valued the business using its cash generated from operations as the starting point, since that already reflects every non-cash item without our having to guess at any of them — including a one-time, non-cash tax benefit and a non-cash gain related to warrant accounting recorded in a recent year. We removed the swings caused by the rapid buildup of receivables and inventory that came with the recent revenue growth, since those reflect timing rather than steady profitability, and we separated a one-time facility investment made a few years ago (which helped fund the later launches) from ordinary, maintenance-level spending. On this basis we estimate the shares are worth somewhere between $0.09 and $0.44, with a middle estimate near $0.28. Given the untested nature of the recent growth and the customer concentration, the margin-of-safety price sits at a significant discount to that middle estimate, and it assumes at least one more quarter confirming the business has stabilized.